Ficerafusp alfa clinical trials
Also written BCA101.
How each study uses ficerafusp alfa has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ficerafusp alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Bicara Therapeutics (3) · Washington University School of Medicine (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Dana-Farber Cancer Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ficerafusp alfa.
- Oct 2027Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPhase 1 · Bicara Therapeutics
Studies
Open first, then newest update. How each study uses ficerafusp alfa has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingPhase 1/2Washington University School of MedicineNCT07552558Written as Ficerafusp alfaReport a problem
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCRecruitingPhase 2/3Bicara TherapeuticsNCT06788990Written as Ficerafusp alfaReport a problem
- A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCRecruitingPhase 2Bicara TherapeuticsNCT07807163Written as Ficerafusp alfaReport a problem
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsRecruitingPhase 1Bicara TherapeuticsNCT04429542Written as BCA101Report a problem
- Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT07529873Written as Ficerafusp alfaReport a problem
- Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT07465276Written as Ficerafusp alfaReport a problem
Tested with established drugs · 6 — they are given beside it
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingPhase 1/2Washington University School of MedicineNCT07552558Written as Ficerafusp alfaReport a problem
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCRecruitingPhase 2/3Bicara TherapeuticsNCT06788990Written as Ficerafusp alfaReport a problem
- A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCRecruitingPhase 2Bicara TherapeuticsNCT07807163Written as Ficerafusp alfaReport a problem
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsRecruitingPhase 1Bicara TherapeuticsNCT04429542Written as BCA101Report a problem
- Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT07529873Written as Ficerafusp alfaReport a problem
- Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT07465276Written as Ficerafusp alfaReport a problem
Codes
What other systems call ficerafusp alfa · ClinicalTrials.gg INT017225
- UNII (FDA) LZ88YF62H2FICERAFUSP ALFAOne source FDA
- NCI Thesaurus C173165Ficerafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LZ88YF62H2 | FICERAFUSP ALFA | One source FDA |
| NCI Thesaurus | C173165 | Ficerafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.